Literature DB >> 1855185

The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas.

R Comtois1, H Beauregard, M Somma, O Serri, N Aris-Jilwan, J Hardy.   

Abstract

From 1962 to 1987, 126 patients underwent trans-sphenoidal surgery for primary treatment of pituitary adenomas unassociated with clinical or biochemical evidence of hormonal overproduction. There were 73 male and 53 female patients (mean age, 50 +/- 12 years). Before surgery, 56% of the patients (70 of 124) had headaches, 74% (94 of 126) had deterioration of vision, and 12% (15 of 126) had ophthalmoplegia. Endocrine evaluation revealed the presence of hypogonadism in 75% (87 of 115), adrenal insufficiency in 36% (46 of 126), and hypothyroidism in 18% (21 of 122). Plasma prolactin was increased in 65% (56 of 86) with a mean level of 39 +/- 14 micrograms/l (normal, 3 to 20 micrograms/l). Radiologic enlargement of the sella turcica was documented in all cases: 67% (84 of 126) had enclosed and 33% (42 of 126) had invasive adenomas. After surgery, vision was normalized or improved in 75% (71 of 94) of the patients. Thyroid, adrenal, and gonadal functions were improved in 14% (three of 22), 41% (19 of 46), 11% (ten of 87), were unchanged in 82% (100 of 122), 77% (97 of 126), 89% (102 of 115), and worsened in 15% (19 of 22), 8% (ten of 126), 3% (102 of 115), respectively. Permanent diabetes insipidus occurred in 5% (seven of 126). Two patients died during the immediate postoperative period. The recurrence rate in patients with a mean follow-up of 6.4 +/- 4.2 years was 21% (15 of 71). These data indicate that trans-sphenoidal microsurgery is an effective and safe initial treatment for patients with nonsecreting pituitary adenoma and may reverse hypopituitarism.

Entities:  

Mesh:

Year:  1991        PMID: 1855185     DOI: 10.1002/1097-0142(19910815)68:4<860::aid-cncr2820680431>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  38 in total

1.  Long-term results of radiation therapy for pituitary adenoma.

Authors:  M Kokubo; K Sasai; Y Shibamoto; T Aoki; N Oya; M Mitsumori; J A Takahashi; N Hashimoto; M Hiraoka
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

2.  Experience in management of 51 non-functioning pituitary adenomas: indications for post-operative radiotherapy.

Authors:  C Alameda; T Lucas; E Pineda; M Brito; J G Uría; R Magallón; J Estrada; B Barceló
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

3.  Outcome of pituitary hormone deficits after surgical treatment of nonfunctioning pituitary macroadenomas.

Authors:  Orsalia Alexopoulou; Valérie Everard; Martine Etoa; Edward Fomekong; Stéphane Gaillard; Fabrice Parker; Christian Raftopoulos; Philippe Chanson; Dominique Maiter
Journal:  Endocrine       Date:  2021-04-14       Impact factor: 3.633

4.  Evaluation of modern pathologic nomenclature, tumor imaging and treatment of pituitary adenomas in a recent surgical series.

Authors:  A Y Cheung; T Sligh; S Bauserman; G Schultz
Journal:  J Neurooncol       Date:  1998-04       Impact factor: 4.130

Review 5.  Guidelines in the management of CNS tumors.

Authors:  Navid Redjal; Andrew S Venteicher; Danielle Dang; Andrew Sloan; Remi A Kessler; Rebecca R Baron; Constantinos G Hadjipanayis; Clark C Chen; Mateo Ziu; Jeffrey J Olson; Brian V Nahed
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

6.  Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas.

Authors:  Jian Gong; Yunge Zhao; Rana Abdel-Fattah; Samson Amos; Aizhen Xiao; M Beatriz S Lopes; Isa M Hussaini; Edward R Laws
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

7.  Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas.

Authors:  L A Behan; E P O'Sullivan; N Glynn; C Woods; R K Crowley; T K Tun; D Smith; C J Thompson; A Agha
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

Review 8.  Radiotherapy of nonfunctioning and gonadotroph adenomas.

Authors:  Andrew A Kanner; Benjamin W Corn; Yona Greenman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

9.  Clinical significance of Ki-67 labeling index in pituitary macroadenoma.

Authors:  Kyung-Il Paek; Seon-Hwan Kim; Shi-Hun Song; Seung-Won Choi; Hyeon-Song Koh; Jin-Young Youm; Youn Kim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

10.  Stereotactic Radiosurgery with the CyberKnife for Pituitary Adenomas.

Authors:  Chul Bum Cho; Hae Kwan Park; Won Il Joo; Chung Kee Chough; Kyung Jin Lee; Hyoung Kyun Rha
Journal:  J Korean Neurosurg Soc       Date:  2009-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.